All In Biotech

Drug Trial Radar · NCT03869892

Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.

An Open-label, Randomised, Phase III Study cOmparing trifLuridine/Tipiracil (S 95005) in Combination With Bevacizumab to Capecitabine in Combination With Bevacizumab in firST-line Treatment of Patients With metastatIC Colorectal Cancer Who Are Not candidatE for Intensive Therapy (SOLSTICE Study)

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 856 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

856

Actual

Start

Mar 21, 2019

Primary completion

Jun 29, 2021

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Institut de Recherches Internationales ServierAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
ADIR, a Servier Group company
First posted
Mar 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to demonstrate the superiority of S 95005 in combination with bevacizumab over capecitabine in combination with bevacizumab.

Conditions

  • Metastatic Colorectal Cancer

Interventions

  • Trifluridine/tipiracil hydrochloride (S95005)Drug

    Film-coated tablets of S 95005 (35 mg/m²/dose) will be administered orally twice a day (BID), within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest; This treatment cycle will be repeated every 4 weeks.

  • CapecitabineDrug

    Film-coated tablets, Capecitabine (1250 mg/m²/dose) will be administered orally BID on Days 1-14 of each cycle. This treatment cycle will be repeated every 3 weeks.

  • Bevacizumab experimentalBiological

    Concentrate for solution for infusion, Bevacizumab (5 mg/kg, IV) administered every 2 weeks (Day 1 and Day 15). This treatment cycle will be repeated every 4 weeks.

  • Bevacizumab controlBiological

    Concentrate for solution for infusion, Bevacizumab (7.5 mg/kg, IV) will be administered on Day 1 of each cycle.This treatment cycle will be repeated every 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: Up to 24 months

Locations

190 sites in 25 countries. Site status is shown where the registry gives one.

  • Centro de Oncología e Investigación de Buenos Aires COIBA

    Berazategui, Argentina

  • Hospital de Gastroenterología Dr. Carlos Borino Udaondo Oncology Unit

    Buenos Aires, Argentina

  • Fundación Favaloro Oncology Unit

    Buenos Aires, Argentina

  • Instituto Alexander Fleming

    Buenos Aires, Argentina

  • Hospital Universitario CEMIC Servicio de Oncología, Unidad de tumores gastrointestinales

    Buenos Aires, Argentina

  • Centro Oncológico Riojano Integral CORI Fundación CORI para la Investigación y Prevención del Cáncer

    La Rioja, Argentina

  • Fundación COIR Centro Oncológico de Interación Regional

    Mendoza, Argentina

  • Centro Médico San Roque

    San Miguel de Tucumán, Argentina

  • Instituto de Oncología de Rosario

    Santa Fe, Argentina

  • ISIS Centro especializado

    Santa Fe, Argentina

  • Blacktown Hospital Cancer and Haematology Centre

    Blacktown, Australia

  • Frankston Private Peninsula and Southeast Oncology Group

    Frankston, Australia

  • Lake Macquarie Private Hospital

    Gateshead, Australia

  • St George Hospital St George Hospital Cancer Care Centre

    Kogarah, Australia

  • Adventist HealthCare Integrated Cancer Centre

    Wahroonga, Australia

  • Southern Medical Day Care Centre

    Wollongong, Australia

  • Med. Universität Graz Klinische Abteilung für Onkologie

    Graz, Austria

  • Medizinische Universität Innsbruck Univ.-Klinik für Innere Medizin V

    Innsbruck, Austria

  • Ordensklinikum Linz Barmherzige Schwestern Interne I

    Linz, Austria

  • Landeskrankenhaus (SALK) Universitätsklinik für Innere Medizin III (SALK)

    Salzburg, Austria

  • Universitätsklinikum St. Pölten Klinische Abteilung für Innere Medizin I

    Sankt Pölten, Austria

  • Allgemeines Krankenhaus - Universitätskliniken Klinische Abteilung für Onkologie

    Vienna, Austria

  • Hospital do Câncer de Barretos - Fundação Pio XII Unidade de Pesquisa Clínica

    Barretos, Brazil

  • Cenantron - Clinica

    Belo Horizonte, Brazil

  • Sirio Libanes DF - Centro de Oncologia de Braslia do Sirio- Centro Intergrado de Pesquisa

    Brasília, Brazil

  • Centro de Pesquisa Hospital de Caridade de Ijuí Unidade de Pesquisa Clínica

    Ijuí, Brazil

  • Hospital Mae de Deus Oncologia

    Porto Alegre, Brazil

  • Hospital São Rafael Centro Intergrado de Pesquisa

    Salvador, Brazil

  • CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncol Centro Intergrado de Pesquisa

    Santo André, Brazil

  • Hospital de Base Centro Integrado de Pesquisa

    São José do Rio Preto, Brazil

  • ICESP - Instituto do Câncer do Estado de São Paulo Centro Integrado de Pesquisa

    São Paulo, Brazil

  • Hospital A C Camargo Unidade de Pesquisa Clinica

    São Paulo, Brazil

  • "Complex oncology center - Burgas" EOOD Department of medical oncology

    Burgas, Bulgaria

  • "Multiprofile hosp. for active treatmen Dr. Tota Venkova" AD Department of medical oncology

    Gabrovo, Bulgaria

  • "Complex oncology center - Plovdiv" EOOD, IInd base Dpt. of Med. oncology and onc. diseases in gastroenterology

    Plovdiv, Bulgaria

  • "Medical Center Nadezhda Clinical" EOOD Medical Oncology Department

    Sofia, Bulgaria

  • "UMHAT Sv. Ivan Rilski" EAD Clinic of clinical hematology, Dpt. of medical oncology

    Sofia, Bulgaria

  • MHAT Serdika EOOD Department of Medical Oncology

    Sofia, Bulgaria

  • Spec. hospital for active treatment of oncology dis. EOOD Department of medical oncology and palliative care

    Sofia, Bulgaria

  • SHAT of oncology diseases Dr. Marko Antonov Markov" EOOD Department of medical oncology and palliative therapy

    Varna, Bulgaria

Showing 40 of 190 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.